Patents by Inventor Yongguo Li

Yongguo Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210196683
    Abstract: A pharmaceutical combination. The pharmaceutical combination contains a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic marker thereof, a crystalline form thereof, a hydrate, a solvate, a diastereoisomer or an enantiomer form, and a biguanide hypoglycemic drug. A pharmaceutical composition and a fixed dose combination preparation as well as a preparation method and use of the pharmaceutical composition and the fixed dose combination preparation.
    Type: Application
    Filed: May 28, 2019
    Publication date: July 1, 2021
    Inventors: Li Chen, Yongguo Li, Gaosen Wang
  • Publication number: 20210196682
    Abstract: Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose of a compound preparation, and the methods for preparing the pharmaceutical composition and the fixed dose of the compound preparation and the uses thereof.
    Type: Application
    Filed: May 28, 2019
    Publication date: July 1, 2021
    Inventors: Li Chen, Yongguo Li, Gaosen Wang, Huisheng Gao
  • Publication number: 20200179488
    Abstract: The present invention relates to a secretin receptor modulator for use in the prevention and/or treatment of a disease or disorder of energy homeostasis, wherein (a) said secretin receptor modulator is a secretin receptor agonist and said disease or disorder is obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia, high blood pressure or metabolic syndrome, whereby the secretin receptor agonist increases non-shivering thermogenesis in brown adipocytes and/or increases the expression of uncoupling protein 1 (UCP1) in brown adipocytes and/or decreases food intake in a UCP1-dependent manner resulting in the prevention and/or treatment of said disease or disorder; or (b) said secretin receptor modulator is a secretin receptor antagonist and said disease or disorder is cachexia.
    Type: Application
    Filed: May 23, 2017
    Publication date: June 11, 2020
    Inventors: Martin KLINGENSPOR, Sarah-Madeleine GABLER, Yongguo LI
  • Patent number: 10669255
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: June 2, 2020
    Assignee: HUA MEDICINE (SHANGHAI) LTD.
    Inventors: Li Chen, Yongguo Li
  • Publication number: 20190328713
    Abstract: Disclosed is a solid dispersion and a preparation method therefor. The solid dispersion contains a glucokinase activator, an isotopic label thereof, or a medicinal salt thereof and a polymer support. Further disclosed is a solid dispersion composition containing the solid dispersion and an excipient. Also disclosed is an oral preparation of the glucokinase activator, containing the solid dispersion or the solid dispersion composition. Also disclosed is a tablet and a capsule of the glucokinase activator and a preparation method therefor. In addition, also disclosed is the uses of the solid dispersion, the solid dispersion composition and the oral preparations comprising the tablet and the capsule, which can be used for treating and/or preventing selected diseases or medical conditions and especially one or more diseases selected from type I diabetes mellitus, type II diabetes mellitus, impaired glucose tolerance, impaired fasting glucose and hyperglycemia.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 31, 2019
    Applicant: Hua Medicine (Shanghai) Ltd.
    Inventors: Li Chen, Yongguo Li, Gaosen Wang
  • Publication number: 20190100506
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.
    Type: Application
    Filed: April 6, 2016
    Publication date: April 4, 2019
    Inventors: Li CHEN, Yongguo LI
  • Patent number: 8258149
    Abstract: The invention provides novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein, compositions including the compounds and methods of preparing and using the compounds.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: September 4, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Li Chen, Lichun Feng, Yongguo Li, Guolong Wu
  • Publication number: 20100286396
    Abstract: The invention provides novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein, compositions including the compounds and methods of preparing and using the compounds.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 11, 2010
    Inventors: Li Chen, Lichun Feng, Yongguo Li, Guolong Wu